Related Experiment Video
Updated: Aug 15, 2026

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
Published on: October 10, 2012
Treatment of type 1 diabetes using a pen-style delivery system and a preparation combining short- and
1Third Department of Internal Medicine, Okayama University Medical School, Japan.
Abstract:
A patient with insulin-dependent diabetes mellitus (type 1 diabetes) was admitted to hospital after complaining of general fatigue and weight loss. To control hyperglycaemia, the patient was given a conventional form of insulin subcutaneously twice daily. Although this conventional insulin replacement therapy effectively controlled the symptoms, it did not improve the metabolic state and eventually the patient was re-admitted due to a worsening of his condition. The patient was then given a new preparation of both short- and intermediate-acting forms of insulin, administered twice daily using a new, 'dial-a-dose' pen delivery system. Comparative studies of blood insulin dynamics revealed that this new method of delivery resulted in a circadian blood glucose pattern closely approximating normal levels, the complete elimination of subjective symptoms and the normalization of basal insulin secretory patterns. The clear superiority of the new delivery system and the combination insulins in relation to the quality of life of this patient is demonstrated.
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type I Diabetes I: Introduction

